The health benefits of retatrutide are generating considerable interest in metabolic medicine, as early clinical data suggest this investigational triple receptor agonist may offer meaningful improvements in body weight, blood glucose, liver fat, and cardiometabolic risk markers. Developed by Eli Lilly, retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors — a mechanism that distinguishes it from currently approved therapies such as semaglutide and tirzepatide. Whilst Phase 2 trial results are promising, retatrutide has not yet received MHRA or EMA approval and remains available only within authorised clinical trials. This article summarises what the current evidence shows and what to expect next.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational triple receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, producing more pronounced effects on appetite, insulin secretion, and energy expenditure than single or dual agonists.

Retatrutide is an investigational injectable medication currently under clinical development by Eli Lilly. It belongs to a novel class of agents known as triple receptor agonists, meaning it simultaneously activates three distinct hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple mechanism distinguishes retatrutide from existing approved therapies such as semaglutide (a GLP-1 agonist) and tirzepatide (a dual GLP-1/GIP agonist).

Each receptor pathway is thought to contribute differently to metabolic regulation, though many of these effects remain under investigation in humans. GLP-1 receptor activation reduces appetite, slows gastric emptying, and improves insulin secretion. GIP receptor activation enhances insulin release in response to meals; a role in fat metabolism has been proposed based on preclinical and early clinical data, but this has not been firmly established in humans. Glucagon receptor activation is hypothesised — based largely on preclinical evidence — to increase energy expenditure and promote hepatic fat reduction; however, the precise contribution of this pathway in humans is not yet fully characterised.

By engaging all three pathways simultaneously, retatrutide is designed to produce a more pronounced and sustained effect on body weight, blood glucose regulation, and metabolic function than single or dual agonists. In Phase 2 trials, it was administered as a once-weekly subcutaneous injection; however, the final dosing regimen and administration schedule may differ if the medicine is ultimately licensed, and these details remain investigational. It is important to note that retatrutide has not yet received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and it remains an experimental therapy at this stage.

Clinical Evidence for Weight Loss and Metabolic Health

A Phase 2 trial published in NEJM (2023) reported approximately 24.2% mean body weight reduction over 48 weeks at the highest dose, alongside improvements in fasting glucose, insulin sensitivity, triglycerides, and waist circumference.

The most substantial early evidence for the potential health benefits of retatrutide comes from a Phase 2 clinical trial published in The New England Journal of Medicine in 2023 (Jastreboff et al., NEJM 2023). In this randomised, double-blind, placebo-controlled study, adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity — but without type 2 diabetes — received retatrutide or placebo over 48 weeks. Participants receiving the highest dose (12 mg weekly) achieved a mean body weight reduction of approximately 24.2% over 48 weeks.

Whilst these results are notable, direct comparisons with currently approved agents should be interpreted with caution: such comparisons are indirect, based on different trial designs, populations, durations, and background interventions (including lifestyle counselling provided alongside study drug), and cannot be treated as equivalent to head-to-head evidence.

Beyond weight reduction, the trial demonstrated improvements in several metabolic markers:

• Fasting blood glucose and HbA1c levels were reduced, suggesting improved glycaemic control; the magnitude of HbA1c change in this non-diabetic population was modest, as would be expected

• Fasting insulin levels decreased, indicating improved insulin sensitivity

• Triglyceride and lipid profiles showed favourable changes, which may reduce cardiometabolic risk

• Waist circumference was substantially reduced, reflecting a decrease in visceral (abdominal) adiposity

These findings are particularly relevant given that excess visceral fat is strongly associated with type 2 diabetes, cardiovascular disease, and metabolic syndrome. Importantly, the long-term durability of weight loss after discontinuation of retatrutide is not yet known, and Phase 3 data are needed to address this question. The ongoing Phase 3 clinical programme (TRIUMPH) is evaluating retatrutide's efficacy and safety in larger, more diverse populations, including people with type 2 diabetes and obesity-related complications. Until Phase 3 data are available and regulatory review is complete, the full clinical profile of retatrutide remains under investigation, and all findings should be interpreted with appropriate caution.

Potential Benefits for Cardiovascular and Liver Health

Phase 2 data showed reductions in liver fat content on MRI, relevant to MASLD, but dedicated cardiovascular outcomes trials have not yet been completed and cardiovascular benefits remain unconfirmed.

One of the most anticipated potential health benefits of retatrutide lies in its possible impact on cardiovascular and liver health, two areas of significant unmet need in people living with obesity and metabolic disease. The glucagon receptor component of retatrutide's mechanism is of particular interest for liver health, as glucagon signalling is thought to play a role in hepatic fat metabolism, though the precise mechanisms in humans remain under investigation.

In the Phase 2 trial, participants showed reductions in liver fat content as measured by MRI-based proton density fat fraction (MRI-PDFF) assessments, with some individuals demonstrating marked reductions in hepatic steatosis. It is important to note that these MRI-based measurements reflect liver fat content and do not equate to histological resolution of metabolic-associated steatohepatitis (MASH) or liver fibrosis, which would require biopsy-based confirmation. This is clinically significant because metabolic dysfunction-associated steatotic liver disease (MASLD) — previously known as non-alcoholic fatty liver disease (NAFLD) — is estimated to affect approximately 25–30% of adults in the UK (British Liver Trust), and can progress to cirrhosis and liver failure if untreated. There is currently no licensed pharmacological treatment for MASLD in the UK, making retatrutide a potentially important therapeutic candidate, though this remains to be confirmed in Phase 3 trials.

With regard to cardiovascular health, the weight loss and metabolic improvements observed in trials are likely to confer indirect cardiovascular benefits. Reductions in blood pressure, triglycerides, and visceral adiposity are all established cardiovascular risk factors. However, dedicated cardiovascular outcomes trials (CVOTs) for retatrutide have not yet been completed, and it is not yet confirmed whether a CVOT is registered as part of the current TRIUMPH Phase 3 programme. The cardiovascular benefits demonstrated with GLP-1 receptor agonists such as semaglutide (in the SUSTAIN-6 and SELECT trials) cannot automatically be extrapolated to retatrutide, and direct evidence is still awaited. Patients with existing heart disease should discuss their options with their GP or specialist rather than drawing premature conclusions.

Known Risks, Side Effects, and Safety Considerations

The most common side effects are gastrointestinal — including nausea, vomiting, and diarrhoea — with additional class-related risks of pancreatitis and gallbladder disease; long-term safety data are not yet established.

As with all medications in the GLP-1 receptor agonist class, retatrutide is associated with a range of gastrointestinal side effects, which were the most commonly reported adverse events in Phase 2 trials. These include:

• Nausea (reported in a significant proportion of participants, particularly during dose escalation)

• Vomiting and diarrhoea

• Constipation and abdominal discomfort

• Decreased appetite, which, whilst contributing to weight loss, can occasionally lead to inadequate nutritional intake

Most gastrointestinal effects were described as mild to moderate in severity and tended to diminish over time. A structured dose-escalation protocol is used to minimise these effects. Significant vomiting or diarrhoea can lead to dehydration, which may increase the risk of acute kidney injury, particularly in older adults or those taking diuretics or other nephrotoxic medicines; maintaining adequate fluid intake and seeking medical advice if symptoms are severe or prolonged is important.

Based on experience with the broader GLP-1 receptor agonist class (including semaglutide and tirzepatide), the following additional risks are relevant and should be discussed with a healthcare professional:

• Acute pancreatitis: Severe, persistent abdominal pain — particularly pain radiating to the back — may be a sign of pancreatitis and requires urgent medical assessment. Patients should seek immediate medical attention if this occurs.

• Gallbladder disease: Cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) have been reported with GLP-1 class agents. Symptoms such as upper abdominal pain, jaundice, or fever should prompt urgent review.

• Hypoglycaemia: Retatrutide is not expected to cause hypoglycaemia on its own; however, when used alongside insulin or sulfonylureas in people with diabetes, the risk of low blood glucose is increased and monitoring is important.

The addition of glucagon receptor agonism introduces some specific considerations not seen with GLP-1 or GIP agonists alone. Glucagon stimulates hepatic glucose production, which could theoretically affect glycaemic balance; in trials, this appeared to be offset by the GLP-1 and GIP components, but careful monitoring in people with diabetes remains important. There are also theoretical concerns regarding heart rate elevation, as observed with other agents in this class.

Longer-term safety data — including effects on the pancreas, thyroid, bone density, and muscle mass — are not yet fully established for retatrutide. Rapid weight loss may be associated with loss of lean muscle mass, and this warrants monitoring. Preclinical studies with GLP-1 agonists have raised questions about thyroid C-cell tumours in rodents, though this has not been confirmed in humans. The safety of retatrutide in pregnancy, breastfeeding, children and adolescents, and people with severe gastroparesis is unknown; it should only be used within the context of authorised clinical trials.

Patients should not attempt to obtain retatrutide outside of clinical trials, as it is not licensed for use in the UK and any such product would be unregulated and potentially unsafe. Anyone who experiences a suspected side effect from any medicine — including within a clinical trial — is encouraged to report it via the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk). Anyone considering participation in a clinical trial should discuss the risks and benefits thoroughly with a qualified healthcare professional.

Current Regulatory Status in the UK and What to Expect Next

Retatrutide has not been approved by the MHRA or EMA and is only available within authorised clinical trials; NICE-approved weight management options for eligible NHS patients currently include semaglutide and tirzepatide.

As of the time of writing, retatrutide has not been approved for clinical use in the United Kingdom. It has not received a marketing authorisation from the MHRA, nor has it been granted approval by the EMA. It remains an investigational medicinal product (IMP), meaning it is only available within the context of authorised clinical trials. Patients should be cautious of any source claiming to supply retatrutide outside of a regulated trial setting, as such products would be unlicensed and potentially unsafe.

The ongoing TRIUMPH Phase 3 programme is expected to generate the robust, large-scale efficacy and safety data required for a regulatory submission. This programme includes trials in adults with obesity and type 2 diabetes, among other populations. Readers wishing to verify the current scope of the TRIUMPH programme — including whether a dedicated cardiovascular outcomes trial is registered — are encouraged to consult the trial registries at ClinicalTrials.gov or the EU Clinical Trials Register (EudraCT). If Phase 3 results are positive and a regulatory dossier is submitted, the MHRA would conduct an independent review of the evidence before any approval could be granted. NICE would subsequently assess the drug's clinical and cost-effectiveness before recommending whether it should be made available on the NHS.

For patients currently seeking treatment for obesity or type 2 diabetes in the UK, NICE-approved options include structured lifestyle interventions, orlistat, and — more recently — semaglutide (Wegovy, NICE TA875) and tirzepatide (Mounjaro, NICE TA1026) for eligible patients through NHS specialist weight management services. GPs can refer patients to these services based on NICE eligibility criteria. Further information is available from the NHS, NICE, and the MHRA.

Retatrutide represents a genuinely promising development in metabolic medicine, but it is essential that patients and clinicians await the outcome of rigorous Phase 3 trials and regulatory review before drawing firm conclusions about its place in therapy. Staying informed through reputable sources such as the NHS (nhs.uk), NICE (nice.org.uk), and MHRA (gov.uk/mhra) is strongly advised.

Frequently Asked Questions